Medpace Holdings, Inc. Common Stock (MEDP) Stock Price
MEDPStock
$618.47+18.66%52W
Market Cap$17.26B
P/E38.27x
PEG Ratio2.99
Div yield—
Beta1.11
MEDP Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)9.03%
Price vs S&P 500 (4W)0.41%
PEG Ratio2.99
VGM Score55.42
P/E Ratio (Annual)38.27x
MEDP Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $4.00 | $4.25 | +6.15%(+$0.25) | |
| Q1 2026 | $3.96 | $4.28 | +8.20%(+$0.32) | |
| Q4 2025 | $4.23 | $4.67 | +10.50%(+$0.44) | |
| Q3 2025 | $3.57 | $3.86 | +8.10%(+$0.29) | |
| Q2 2025 | $3.00 | $3.10 | +3.47%(+$0.10) |
MEDP Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.60
3.60
3.40
3.40
Industry Peers — R&D — Physical Sciences(17)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|---|---|---|
MEDPMedpace Holdings, Inc. Common Stock | F | B | B | 38.3x | 110.2% | 22.3% | — | $618.47 |
| IQVIQVIA Holdings Inc. | D | C | A | 32.3x | 21.9% | 7.5% | — | $266.90 |
| INCYIncyte Genomics Inc | C | B | B | 17.8x | 29.6% | 14.0% | — | $113.07 |
| CRLCharles River Laboratories International, Inc. | F | D | A | — | -7.7% | 6.5% | — | $300.15 |
| ICLRIcon Plc | C | C | B | 57.3x | 0.8% | 24.1% | — | $170.18 |
| ABSIAbsci Corporation Common Stock | F | F | B | — | -59.2% | -10.1% | — | $8.25 |
| OABIOmniAb, Inc. Common Stock | F | B | A | — | -16.6% | -4.3% | — | $4.59 |
| NRCNRC Health Common Stock | D | D | B | 38.4x | 48.5% | 0.6% | 1.2% | $20.15 |
| MXCTMaxCyte, Inc. Common Stock | C | D | B | — | -21.0% | 4.8% | — | $1.30 |
| IBACIB Acquisition Corp. Common Stock | — | D | C | 15.9x | -3.7% | — | — | $10.86 |
| ONMDOneMedNet Corp Class A Common Stock | D | A | D | — | -6.8% | — | — | $4.51 |
About Medpace Holdings, Inc. Common Stock
Medpace is a late-stage contract research organization providing comprehensive drug development and clinical trial services to small and midsize biotech, pharmaceutical, and medical device companies. The company offers additional capabilities including bioanalytical laboratory services and imaging solutions. With over 5,400 employees across 40 countries and 30+ years of industry experience, Medpace maintains global operations headquartered in Cincinnati, Ohio, with a substantial presence across North America, Europe, Asia, and other regions.